Corcept Therapeutics

Corcept Therapeutics is facing a shareholder investigation due to allegations of misleading investors about the efficacy and commercial prospects of its drug relacorilant and its communications with the FDA. The company's stock price has significantly declined, wiping out $3.2 billion in market capitalization.

Corcept Therapeutics is facing a class action lawsuit alleging that its officers made false and misleading statements regarding the clinical trials and regulatory prospects of its drug relacorilant. This could lead to significant financial damages and reputational harm for the company.

Corcept Therapeutics faces a securities fraud lawsuit after the United States===Food and Drug Administration declined to approve its New Drug Application for relacorilant. The company's stock price fell significantly following the news, indicating a negative market reaction to the regulatory setback and subsequent legal action.

Corcept Therapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding the approval likelihood of its drug relacorilant. The U.S. Food and Drug Administration issued a Complete Response Letter, causing a significant drop in Corcept Therapeutics's stock price.

Corcept Therapeutics faces a class action lawsuit due to alleged undisclosed concerns from the FDA regarding its relacorilant program, which could impact its drug development and market standing.